A Genetic Risk-Stratified, Phase II Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated Chronic Lymphocytic Leukemia (CLL): Final Results of Cancer and Leukemia Group B (CALGB) 10404 (Alliance)
- Citation:
- J Clin Oncol vol 35 (15 suppl) abstr 7503
- Meeting Instance:
- ASCO 2017
- Year:
- 2017
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- Yes
- Parents:
- None
- Children:
- 2767
- Pharmas:
- Celegene
- Grants:
- U10CA180820, U10CA180821, U10CA180882, U10CA180828, U10CA180888, NCTN CA180863, CCSRI 021039
- Corr. Author:
- Authors:
- Amy S. Ruppert John C. Byrd Nyla A. Heerema Mitchell Smith John Godwin Stephen Couban Todd A. Fehniger Michael Thirman Alese E. Halvorson Bercedis L. Peterson Martin S. Tallman Frederick R. Appelbaum Richard M. Stone Sue Robinson Julie E. Chang Sumithra J. Mandrekar Richard A. Larson
- Networks:
- LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-OH007, LAPS-WI020, OH070, PCRC
- Study
- CALGB-10404
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: